Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
developmental toxicity
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Comparable to guideline study with restrictions

Data source

Referenceopen allclose all

Reference Type:
publication
Title:
Assessment of teratogenic potential of 1,2,3-, 1,2,4- and 1,2,5-trichlorobenzenes in rats.
Author:
Black WD et al
Year:
1988
Bibliographic source:
Bull. Environ. contam. Toxicol 41, 719-726
Reference Type:
publication
Title:
Evaluation of risks to health from environmental exposure in Canada
Author:
Giddings M
Year:
1994
Bibliographic source:
Carcino.Ecotox. Revs. C12, 517-525
Reference Type:
publication
Title:
A teratological evaluation following oral administration of trichloro- and dichlorobenzene to the rat.
Author:
Ruddick VK et al
Year:
1983
Bibliographic source:
Teratology 27, 73A-74A

Materials and methods

Test guideline
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
Housing and feeding conditions not reported; exposure too short; number of animals exposed too small; weight of dams recorded only at 22nd day of gestation; food consumption, number of corpora lutea, sex of each foetus not recorded
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
1,2,3-trichlorobenzene
EC Number:
201-757-1
EC Name:
1,2,3-trichlorobenzene
Cas Number:
87-61-6
Molecular formula:
C6H3Cl3
IUPAC Name:
1,2,3-trichlorobenzene
Details on test material:
- Name of test material (as cited in study report): 1,2,3-trichlorobenzene
- Analytical purity: 99.5%

Test animals

Species:
rat
Strain:
Sprague-Dawley

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Duration of treatment / exposure:
day 6 - day 15 of gestation
Frequency of treatment:
once daily
No. of animals per sex per dose:
Each groups consisted of approximately 13-14 dams

Control animals:
yes, concurrent vehicle
Details on study design:
Sex: female
Duration of test: until day 22

Results and discussion

Results: maternal animals

Effect levels (maternal animals)

Dose descriptor:
NOAEL
Effect level:
ca. 150 mg/kg bw/day
Basis for effect level:
other: maternal toxicity

Results (fetuses)

Effect levels (fetuses)

Dose descriptor:
NOAEL
Effect level:
ca. 600 mg/kg bw/day
Basis for effect level:
other: teratogenicity

Fetal abnormalities

Abnormalities:
not specified

Overall developmental toxicity

Developmental effects observed:
not specified

Any other information on results incl. tables

--None of the animals displayed any signs of toxicity, 
--Body weight development was not affected.
--Mortality
300 mg-group: 1 dam died
control group: 1 dam died

--Fetal data
no difference to the concurrent control in
number of dams at term, nimber of dams inseminated, resorptions, dead  fetuses, fetal weights, litter size
no viseral or skeletal abnormalities
- Skeletal deviations 
(number of pups affected/number of litters affected 150 mg-gr., 300  mg-gr., 600 mg-gr versus control): 
Sternal anomalies: 1/1, 1/1, 13/3 versus 1/1
wavy ribs: 0, 1/1, 1/1 versus 1/1
14th rib: 1/1, 0, 0 versus 0
13th rib(short): 1/1, 0, 0 versus 0

----Maternal data (significant changes):
--increase in relative liver weight: 
600 mg-gr: 5.8 % versus 5.1% of control
--increase in ADPM activity:
600 mg-gr: 27.3 nanomoles formaldehyde/hr/mg protein versus 
22.8 nanomoles formaledhyde/hr/mg protein of control
--decrease in hemoglobin concentration:
500mg-gr, 300 mg-gr: 11.3g/dl, 11.3g/dl versus 12.0g/dl of control
--decrease in hematocrit levels:
600 mg-gr: 31.1% versus 33.3% of controls
--histopathology.
-thyroid, 300 mg-gr and 600 mg-gr: reduction in follicle size accompanied  by agular collapse; 600 mg-gr:increased epithelial height accompanied by  cytoplasmatic vacuolation
-liver, 300 mg-gr, 600 mg-gr: mild increased periportal cytoplasmic  eosinophilia and mild anisokaryosis of hepatocellular nuclei
-spleen
mild increased hematopoiesis in some females (no further information)
--TRCB residues:
only found in traces in the perirenal fat of the 300 mg-gr. and 600 mg-gr  consistting of 0.02 and 0.4 ppm, respectively

Applicant's summary and conclusion